Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Kate Smith
Authored Items
New Data on Ixazomib Maintenance Support Long-Term Oral Therapy in Patients with Myeloma
Kate Smith
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
in
Multiple Myeloma
Weekly Carfilzomib Safe and Effective
Kate Smith
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
in
Multiple Myeloma
Monoclonal Antibodies Poised to Be “Blockbusters” in Myeloma
Kate Smith
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
in
Multiple Myeloma
Stem-Cell Mobilization More Cost-Effective with Plerixafor
Kate Smith
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Financial Toxicity Impacts Treatment Adherence
Kate Smith
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
American-Style Capitalism Drives Drug Development: Cancer Therapies Targeting Small Subpopulations Dictate Prices
Kate Smith
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
The Hematology Pipeline Is Abundant
Wayne Kuznar
,
Kate Smith
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
in
Emerging Therapies
Value and Cost-Effectiveness Analyses Should Be Included in Reimbursement Decisions
Kate Smith
February 2015 Vol 8, Special Issue: Payers' Perspectives in Oncology
Last modified: April 23, 2015